In the middle of the last century, pharmacologists at the University of Melbourne led by Professor Frank Shaw inadvertently discovered that an amino-acridine they were using in other experiments reversed the respiratory depressive effects of morphine. They widened their search for such activity, experimenting with a range of heterocyclic substances and achieving success with a thiazole derivative, provided to them by the Professor of Organic Chemistry at the university, that countered the effects of morphine. Working with chemists and pharmacologists at a company with which Shaw had close links, Nicholas Pty Ltd, they discovered a glutarimide that offered the same benefit in cases of barbiturate intoxication. While this collaboration between pharmacologists and chemists, in industry and university, promised much, neither of these drugs survived into modern medical practice. The reasons for this include the development of better drugs or more appropriate patient care, Shaw’s withdrawal from the work because of illness, and decisions in the company that might have been influenced by increasingly stringent requirements for the registration of new drugs. Nonetheless this was important research that drew on the depth of expertise in pharmacology and chemistry among university researchers and a major Australian company with whom they collaborated and exchanged personnel.

上世纪中叶，由 Frank Shaw 教授领导的墨尔本大学药理学家无意中发现，他们在其他实验中使用的氨基吖啶可以逆转吗啡的呼吸抑制作用。他们扩大了对此类活性的研究，对一系列杂环物质进行了实验，并通过该大学有机化学教授提供给他们的噻唑衍生物取得了成功，该衍生物可以对抗吗啡的作用。在与 Shaw 有密切联系的公司 Nicholas Pty Ltd 中，他们与化学家和药理学家合作，发现了一种戊二酰亚胺，在巴比妥类中毒的情况下也能提供同样的益处。虽然药理学家和化学家之间的这种合作，在工业界和大学，承诺了很多，这些药物都没有在现代医疗实践中幸存下来。其原因包括开发更好的药物或更合适的患者护理、Shaw 因病退出工作，以及公司的决策可能受到新药注册越来越严格的要求的影响。尽管如此，这是一项重要的研究，它利用了大学研究人员和与他们合作和交流人员的澳大利亚大公司在药理学和化学方面的专业知识的深度。公司的决策可能受到越来越严格的新药注册要求的影响。尽管如此，这是一项重要的研究，它利用了大学研究人员和与他们合作和交流人员的澳大利亚大公司在药理学和化学方面的专业知识的深度。公司的决策可能受到越来越严格的新药注册要求的影响。尽管如此，这是一项重要的研究，它利用了大学研究人员和与他们合作和交流人员的澳大利亚大公司在药理学和化学方面的专业知识的深度。